---
figid: PMC6896088__cancers-11-01775-g004
figlink: /pmc/articles/PMC6896088/figure/cancers-11-01775-f004/
number: F4
caption: The AKT signaling pathway contributes to treatment resistance against targeted
  therapies and chemotherapies in cancers. (a) BRAF inhibition (BRAFi) upregulates
  AKT activity in melanomas with concurrent PTEN loss and activating BRAFv600E mutations.
  This result in AKT-mediated inhibition of the transcription factor Forkhead Box
  O3A (FOXO3A), and reduces the transcriptional upregulation of its pro-apoptotic
  target gene, BIM. Combined pharmacological inhibition of BRAF activity and AKT activity,
  by PI3K inhibition, increases BIM expression and potentiates apoptosis, suggesting
  that AKT activity contributes to the resistance of BRAFV600E mutation-bearing melanomas
  to BRAFi []. (b) Activating mutations in the catalytic subunit of PI3K (PI3KCA)
  also contribute to resistance against chemotherapies in colorectal cancers through
  suppression of pro-apoptotic responses, and inhibition of PI3K can potentiate the
  cytotoxic effects of chemotherapy [].
pmcid: PMC6896088
papertitle: Molecular Mechanisms Underlying Autophagy-Mediated Treatment Resistance
  in Cancer.
reftext: Cally J. Ho, et al. Cancers (Basel). 2019 Nov;11(11):1775.
pmc_ranked_result_index: '58143'
pathway_score: 0.9707556
filename: cancers-11-01775-g004.jpg
figtitle: The AKT signaling pathway contributes to treatment resistance against targeted
  therapies and chemotherapies in cancers
year: '2019'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6896088__cancers-11-01775-g004.html
  '@type': Dataset
  description: The AKT signaling pathway contributes to treatment resistance against
    targeted therapies and chemotherapies in cancers. (a) BRAF inhibition (BRAFi)
    upregulates AKT activity in melanomas with concurrent PTEN loss and activating
    BRAFv600E mutations. This result in AKT-mediated inhibition of the transcription
    factor Forkhead Box O3A (FOXO3A), and reduces the transcriptional upregulation
    of its pro-apoptotic target gene, BIM. Combined pharmacological inhibition of
    BRAF activity and AKT activity, by PI3K inhibition, increases BIM expression and
    potentiates apoptosis, suggesting that AKT activity contributes to the resistance
    of BRAFV600E mutation-bearing melanomas to BRAFi []. (b) Activating mutations
    in the catalytic subunit of PI3K (PI3KCA) also contribute to resistance against
    chemotherapies in colorectal cancers through suppression of pro-apoptotic responses,
    and inhibition of PI3K can potentiate the cytotoxic effects of chemotherapy [].
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - MUT
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - MAP2K1
  - MAP2K2
  - AKT2
  - AKT3
  - AKT1
  - MAPK3
  - MAPK1
  - MTOR
  - FOXO3
  - BCL2L11
genes:
- word: B-RAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: MUT
  symbol: MUT
  source: hgnc_symbol
  hgnc_symbol: MUT
  entrez: '4594'
- word: MUT
  symbol: MUT
  source: hgnc_symbol
  hgnc_symbol: MUT
  entrez: '4594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: FOXO3A
  symbol: FOXO3A
  source: hgnc_prev_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: ERK1/2signaling
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: BIM
  symbol: BIM
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2L11
  entrez: '10018'
chemicals: []
diseases: []
figid_alias: PMC6896088__F4
redirect_from: /figures/PMC6896088__F4
figtype: Figure
---
